Additional file 2 of A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

Hiruma, Shigenori; Shigiyama, Fumika; Hisatake, Shinji; Mizumura, Sunao; Shiraga, Nobuyuki; Hori, Masaaki; Ikeda, Takanori; Hirose, Takahisa; Kumashiro, Naoki

doi:10.6084/m9.figshare.13698082.v1

12933_2021_1228_MOESM2_ESM.docx (17.64 kB)

Additional file 2 of A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

journal contribution

posted on 2021-02-03, 04:31 authored by Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro

Additional file 2. Adverse events (list of observed adverse events).

Funding

Boehringer Ingelheim Eli Lilly Japan

History

Usage metrics

Keywords

DPP-4 inhibitor Early-stage type 2 diabetes mellitus Epicardial fat 123I-BMIPP scintigraphy Myocardial triglyceride content Pericardial fat Preserved cardiac function SGLT2 inhibitor

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 2 of A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

Funding

Boehringer Ingelheim Eli Lilly Japan

History

Usage metrics

Categories

Keywords

Licence

Exports